Enhanced Composition for Obesity and Lipid-Related Metabolic Disorders

The present invention relates to novel compositions and methods for preventing or treating obesity and lipid-related metabolic disorders, offering improved efficacy, safety, and personalized treatment options.

The original patent disclosed a composition for preventing or treating obesity or lipid-related metabolic disorders, but it had limitations in terms of efficacy, side effects, and individual responsiveness. The present inventive concept addresses these limitations by introducing synergistic combinations of steroid sulfatase inhibitors and lipase inhibitors, polyunsaturated fatty acids, and genetic testing modules to enhance weight loss, lipid metabolism, and personalized treatment.

The inventive concept comprises a system for preventing or treating obesity or lipid-related metabolic disorders, featuring a steroid sulfatase inhibitor and a lipase inhibitor administered in a synergistic ratio to enhance weight loss and lipid metabolism. Additionally, the invention encompasses methods for enhancing the efficacy of a steroid sulfatase inhibitor, compositions comprising a steroid sulfatase inhibitor and a polyunsaturated fatty acid, and systems for personalized treatment incorporating genetic testing modules. These novel combinations and methods overcome the limitations of the original patent, providing improved therapeutic outcomes and reduced side effects.

The new claims introduce novel synergistic combinations of steroid sulfatase inhibitors and lipase inhibitors, as well as the use of polyunsaturated fatty acids and genetic testing modules, which are not obvious from the original patent. These innovations provide a significant improvement over the prior art, enabling more effective and personalized treatment of obesity and lipid-related metabolic disorders.

Alternative embodiments of the inventive concept may include varying the ratio of steroid sulfatase inhibitors to lipase inhibitors, using different polyunsaturated fatty acids, or incorporating additional therapeutic agents. Furthermore, the genetic testing module could be adapted for use with different genetic markers or biomarkers, expanding the scope of personalized treatment options.

The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of obesity and lipid-related metabolic disorders. The improved efficacy, safety, and personalized treatment options offered by this invention could lead to a substantial market share and revenue growth.